Gyre Therapeutics (GYRE) Revenue (2010 - 2026)

Gyre Therapeutics (GYRE) has 16 years of Revenue data on file, last reported at $22.5 million in Q1 2026.

• Revenue for Q1 2026 came in at $22.5 million, up 2.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $117.0 million (up 16.3% YoY), and the FY2025 annual result was $116.6 million, up 10.24% from the prior year.
• Revenue declined to $22.5 million in Q1 2026 per GYRE's latest filing, from $37.2 million in the prior quarter.
• Over five years, Revenue peaked at $101.5 million in Q4 2022 and troughed at $794000.0 in Q1 2022.
• A 5-year average of $30.7 million and a median of $27.1 million in 2023 frame the typical range for Revenue.
• The sharpest annual moves came in 2022 and 2023: Revenue soared 4059.67% in 2022, then slumped 73.25% in 2023.
• A 5-year view of Revenue shows it stood at $101.5 million in 2022, then tumbled by 73.25% to $27.1 million in 2023, then gained by 2.67% to $27.9 million in 2024, then surged by 33.45% to $37.2 million in 2025, then plunged by 39.46% to $22.5 million in 2026.
• Business Quant data shows GYRE's Revenue at $22.5 million in Q1 2026, $37.2 million in Q4 2025, and $30.6 million in Q3 2025.